If You Invested in Cyclo Therapeutics, Inc. (CYTH)

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) is a clinical-stage biotechnology company focused on developing medicines for patients and families living with rare and challenging diseases. The company is advancing drug candidates in the field of lysosomal and neurodegenerative disorders, with a primary emphasis on Niemann-Pick Disease Type C1 (NPC1), a rare and fatal genetic disease, and an additional program in early Alzheimer’s disease.

The company’s lead investigational product is Trappsol® Cyclo™, which has received Orphan Drug Designation in both the United States and Europe for the treatment of NPC1, as well as Fast Track and Rare Pediatric Disease designations in the United States. Trappsol® Cyclo™ is being evaluated in multiple formal clinical trials for NPC1 and in a Phase 2b clinical trial in early Alzheimer’s disease. According to company disclosures, additional indications for the active ingredient in Trappsol® Cyclo™ are in development.

Focus on Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics describes NPC1 as a rare genetic disease that affects approximately 1 in 100,000 live births globally. Most individuals with NPC have mutations in the NPC1 gene, with a smaller proportion having mutations in the NPC2 gene. The disease is characterized by impaired transport and processing of cholesterol within cells, leading to cholesterol accumulation and dysfunction in multiple organs, including the brain, liver, spleen, lungs and other tissues, and often results in premature death.

The company is conducting a pivotal Phase 3 global trial known as TransportNPC™, a randomized, double-blind, placebo-controlled, parallel-group, multicenter study. This trial is designed to evaluate the safety, tolerability and efficacy of intravenous Trappsol® Cyclo™ plus standard of care compared with placebo plus standard of care in patients with NPC1. Company statements describe TransportNPC™ as the most comprehensive controlled pivotal study for NPC1 in terms of patient size, global footprint, duration and clinical outcomes for an investigational therapy.

The TransportNPC™ study has a planned duration of 96 weeks with a 48-week comparative interim analysis. The company has reported completion of enrollment in the pivotal trial, including 93 planned and one over-enrolled patient, and an associated single-arm sub-study. The sub-study, conducted under a Paediatric (Pediatric) Investigational Plan, enrolls newborns to 3 years of age to evaluate Trappsol® Cyclo™ in very young patients, with a focus on systemic (visceral) aspects of NPC1 and the concept of early intervention.

Clinical Data and Safety Profile

Cyclo Therapeutics has presented preliminary data from its Phase 3 TransportNPC™ study and the open-label sub-study at scientific meetings such as the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium and the WORLDSymposium™ conference dedicated to lysosomal diseases. According to company reports, the safety profile of Trappsol® Cyclo™ in these studies has been consistent with prior completed studies and expanded access experience.

In the ongoing Phase 3 program, the company has reported that the majority of adverse events (AEs) observed to date are mild or moderate in severity, with a limited number of severe events and serious adverse events (SAEs). Company summaries state that no patients have withdrawn from the pivotal study due to safety concerns, and that in the sub-study involving patients under 3 years of age, no SAEs have been considered related or possibly related to the study drug. Preliminary data from a prior Phase 1 study in adult NPC patients indicated central and systemic lipid clearance, and early findings from the sub-study suggest stabilization or improvement on clinical impression scales in many treated patients over 24- and 48-week periods.

Regulatory Strategy and Designations

Cyclo Therapeutics has aligned its development strategy for Trappsol® Cyclo™ with regulatory authorities including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Company communications indicate that, if the 48-week interim data from TransportNPC™ demonstrate statistical significance, the company, in alignment with these agencies, intends to submit a New Drug Application (NDA) to the FDA and a Marketing Authorization Application (MAA) to the EMA based on the interim dataset.

The company has received Orphan Drug Designation for Trappsol® Cyclo™ to treat NPC1 in both the U.S. and EU, as well as Fast Track and Rare Pediatric Disease designations in the U.S. The Rare Pediatric Disease designation is described by the company as one of the key requirements for eligibility to receive a Priority Review Voucher upon marketing authorization in the United States.

Alzheimer’s Disease Program and Intellectual Property

Beyond NPC1, Cyclo Therapeutics is conducting a Phase 2b clinical trial using Trappsol® Cyclo™ administered intravenously in patients with early Alzheimer’s disease. This program is based on data from an Expanded Access program for Alzheimer’s disease. The company has reported receiving a U.S. patent covering the use of Trappsol® Cyclo™ for the treatment of Alzheimer’s disease from the U.S. Patent and Trademark Office, as well as a notice of decision to grant a European patent titled “Methods for Treating Alzheimer’s Disease” from the European Patent Office.

According to company statements, these patents are considered important components of its patent estate related to the Alzheimer’s disease asset. Additional indications for the active ingredient in Trappsol® Cyclo™ are described as being in development, although specific additional indications beyond NPC1 and early Alzheimer’s disease are not detailed in the provided materials.

Corporate Background and Evolution

Historical information from earlier descriptions indicates that the business originated as Cyclodextrin Technologies Development, Inc., organized as a Florida corporation on August 9, 1990, with operations beginning in July 1992. The company became a fully reporting public company listed on the OTC Bulletin Board in the mid-1990s and later adopted a holding company structure under the name CTD Holdings, Inc. The original business was formed to market and sell cyclodextrins and related products to the food, pharmaceutical and other industries, and to provide consulting services related to cyclodextrin technology.

As a holding company, CTD Holdings indicated that it would acquire, create and invest in companies developing, marketing or selling products containing cyclodextrins, and it reported operating several wholly owned subsidiaries. Over time, the business evolved into Cyclo Therapeutics, Inc., with a focus on clinical-stage biotechnology and the development of Trappsol® Cyclo™ for rare disease and neurodegenerative indications. The historical information illustrates a transition from a cyclodextrin product and consulting business to a clinical-stage biopharmaceutical company.

Clinical Trial Portfolio

Company disclosures identify four formal clinical trials of Trappsol® Cyclo™ in NPC1, referenced on ClinicalTrials.gov by identifiers NCT02939547, NCT02912793, NCT03893071 and NCT04860960. The pivotal Phase 3 TransportNPC™ study corresponds to NCT04860960. These studies collectively provide efficacy, safety and long-term treatment data across different age groups and disease severities, including an expanded access program and the pediatric sub-study.

For early Alzheimer’s disease, Cyclo Therapeutics is conducting a Phase 2b trial of intravenous Trappsol® Cyclo™ (NCT05607615), supported by prior Expanded Access experience (NCT03624842). Public statements emphasize the company’s intent to use data from these programs to understand the potential role of Trappsol® Cyclo™ in addressing neurodegenerative pathology.

Strategic Transactions and Ownership

Cyclo Therapeutics has engaged in corporate transactions to support its clinical programs. The company reported completing a merger with Applied Molecular Transport Inc. to focus on advancing the TransportNPC™ Phase 3 global study. It also entered into an Agreement and Plan of Merger with Rafael Holdings, Inc. and affiliated entities, under which Cyclo Therapeutics would be merged into subsidiaries of Rafael in a two-step merger structure, subject to stockholder approvals and other conditions.

Company communications note that Rafael Holdings is a significant shareholder and holds a substantial portion of Cyclo Therapeutics’ outstanding common stock. Rafael Holdings and other investors, including board members and management, have been cited as participants in warrant exercises that provided additional cash proceeds to Cyclo Therapeutics. These relationships and transactions are presented by the company as part of its strategy to fund and advance the TransportNPC™ program and related clinical activities.

Engagement with Scientific and Patient Communities

Cyclo Therapeutics regularly presents data at international scientific meetings focused on lysosomal and metabolic diseases, including WORLDSymposium™ and the SSIEM Annual Symposium. The company highlights oral and poster presentations covering long-term treatment data, safety and efficacy across multiple clinical studies, and the use of assessment tools to evaluate clinically relevant outcomes in NPC1.

In addition, the company reports ongoing engagement with the NPC community through participation in conferences and patient-focused events such as the Latin American School of Medical and Human Genetics Annual Meeting, the Australian NPC Foundation Conference and the National Niemann-Pick Disease Foundation (NNPDF) Family Support & Medical Conference. These activities are described as part of its efforts to work closely with patients, caregivers and clinicians involved in NPC1.

Stock and Sector Classification

Cyclo Therapeutics, Inc. trades on the Nasdaq under the ticker symbol CYTH. Based on the provided classification, the company operates within the Research and Development in Biotechnology industry and the Professional, Scientific, and Technical Services sector. As a clinical-stage biotechnology issuer, its value proposition to investors centers on the progress, risk and potential outcomes of its clinical and regulatory programs for Trappsol® Cyclo™ in NPC1 and early Alzheimer’s disease, along with the strength of its intellectual property and regulatory designations.